| Carrimycin mixture: R = H, acetyl, or propionyl | |
| Clinical data | |
|---|---|
| Trade names | Bite [1] |
| Other names | Isovalerylspiramycin |
| Legal status | |
| Legal status |
|
| Identifiers | |
| DrugBank | |
| UNII | |
Carrimycin is a macrolide antibiotic. It was approved by the National Medical Products Administration of China in 2019. [1] It is approved for the treatment of acute tracheal bronchitis caused by Haemophilus influenzae , Streptococcus pneumoniae , and for the treatment of acute sinusitis caused by S. pneumoniae, H. influenzae, Streptococcus pyogenes , Moraxella catarrhalis , and Staphylococcus . [2] Carrimycin is mainly used for the treatment of upper respiratory tract infections. [1]
Carrimycin is a mixture of related chemical compounds, carrimycin I through III, which are each ester derivatives of spiramycin. [3]
Carrimycin has also been investigated for the treatment of COVID-19. [2] [4]